Clinical Trials Directory

Trials / Terminated

TerminatedNCT00060008

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Novel Imaging Modalities For Plexiform Neurofibromas

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Children's Hospital of Philadelphia · Academic / Other
Sex
All
Age
25 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a patient's response to treatment, and help plan the most effective treatment. PURPOSE: This diagnostic trial is studying how well FDG-PET and MR perfusion imaging work in finding disease progression and determining response to treatment in patients with neurofibromatosis 1 and plexiform neurofibroma.

Detailed description

OBJECTIVES: * Determine whether fludeoxyglucose F 18 positron emission tomography (FDG-PET) and MR perfusion studies can predict plexiform neurofibroma growth rates in patients with neurofibromatosis 1. * Determine whether FDG-PET and MR perfusion studies can predict the likelihood of response in patients who are undergoing investigational treatment for plexiform neurofibromas. * Identify neuroimaging characteristics that distinguish patients who have responded to therapy from those who have not after completion of treatment. OUTLINE: * Stratum 1: Patients undergo MR perfusion scan with gadopentetate dimeglumine and fludeoxyglucose F 18 positron emission tomography (FDG-PET) at baseline and quantitative MRI evaluation at baseline and 1 year. * Stratum 2: Patients undergo quantitative MRI, MR perfusion scan with gadopentetate dimeglumine, and FDG-PET at baseline and 1 year. PROJECTED ACCRUAL: A total of 48 patients (32 for stratum 1 and 16 for stratum 2) will be accrued for this study.

Conditions

Interventions

TypeNameDescription
RADIATIONfludeoxyglucose F 18
RADIATIONgadopentetate dimeglumine

Timeline

Start date
2002-04-01
Primary completion
2011-05-01
Completion
2011-05-01
First posted
2003-05-07
Last updated
2014-04-04
Results posted
2014-04-04

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00060008. Inclusion in this directory is not an endorsement.